Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Kei-ichiro Arimoto, Leo J.Y. Kim, Balázs Győrffy, Klaus-Peter Knobeloch, Dong-Er Zhang, Hua Cheng, Christoph Burkart, Xiang-Dong Fu, Jeremy N. Rich, Hu Cang, Jun-Bao Fan, Yu Zhou, Hui-Zhong Xu, Ming Yan, Sayuri Miyauchi, Dan Liu
Publikováno v:
Cancer Discov
Type I interferons (IFN), which activate many IFN-stimulated genes (ISG), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing antitumor effects. Here, we report that the I
Autor:
Christine A. Pratilas, Sharmeen Uddin, Amy Allen, Zhan Yao, Jiawan Wang, Ira J. Dunkel, Barry S. Taylor, Neal Rosen, Philip Jonsson, Alice Can Ran Qin, Katia Manova, Sofia Haque, David J. Pisapia, Mary Petriccione, Marc K. Rosenblum
Publikováno v:
Cancer Discovery. 8:1130-1141
BRAFV600E hyperactivates ERK and signals as a RAF inhibitor–sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely chara
Autor:
Jonathan H. Sheehan, Carlos L. Arteaga, Michael F. Berger, James P. Koch, Richard E. Cutler, Vincent A. Miller, Ariella B. Hanker, Rebecca J. Nagy, Gregory Sliwoski, David M. Hyman, Christine M. Lovly, Jie He, Alshad S. Lalani, Jens Meiler, Monica Red Brewer, David B. Solit, Richard B. Lanman, Darren Cross
Publikováno v:
Cancer Discovery. 7:575-585
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization w
Autor:
Christopher J. Morrow, Zhiqiang Li, Joanne Wilson, Sarat Chandarlapaty, Kathryn E. Carlson, Pedram Razavi, Teresa S. Martin, José Baselga, Anne U. Goeppert, Mandy Lawson, Wai Lin Wong, Elisa de Stanchina, Anne Marie Mazzola, Geoffrey L. Greene, John A. Katzenellenbogen, Hazel M. Weir, Aaron Smith, Weiyi Toy, Sharmeen Uddin, Sean W. Fanning
Publikováno v:
Cancer Discovery. 7:277-287
Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independen
Autor:
Aram F. Hezel, Nabeel Bardeesy, Cyril H. Benes, Jia-Chi Yeo, James T. Webber, Kevan M. Shokat, Travis Sullivan, Benjamin P. Kleinstiver, Roger L. Jenkins, Ultan McDermott, Yusuke Mizukami, Leah J. Damon, Regina K. Egan, Lei Shi, Supriya K. Saha, J. Keith Joung, John D. Gordan, Patricia Greninger, Rebecca S. Levin, Andrew S. Liss, Yasutaka Kato, Andrew X. Zhu, Kimberly M. Rieger-Christ, Mortada S. Najem, Lipika Goyal, Cristina R. Ferrone, Phuong Vu, Mathew J. Garnett
Publikováno v:
Cancer discovery, vol 6, iss 7
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tr
Autor:
Ilaria Conti, Sheng-Bin Peng, James J. Starling, Igor Mochalkin, Henry James Robert, Sean Buchanan, Robert D. Van Horn, Lysiane Huber, Gregory D. Plowman, Swee Seong Wong, Youyan Zhang, Vipin Yadav, Yong Gang Yue, Shih-Hsun Chen, Tinggui Yin
Publikováno v:
Cancer Discovery. 6:300-315
We have identified previously undiscovered BRAF in-frame deletions near the αC-helix region of the kinase domain in pancreatic, lung, ovarian, and thyroid cancers. These deletions are mutually exclusive with KRAS mutations and occur in 4.21% of KRAS
Autor:
Jens Meiler, Jonathan H. Sheehan, Timothy M. Shaver, Jean-Nicolas Gallant, Sally York, Mark G. Kris, Jennifer A. Pietenpol, Marc Ladanyi, Siraj M. Ali, Christine M. Lovly, Monica Red Brewer, Vincent A. Miller, Doron Lipson, Mark Bailey, Raghu Chandramohan
Publikováno v:
Cancer Discovery. 5:1155-1163
Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas. Such mutations, which present most commonly as small in-frame deletions in exon 19 or point mutations in exon 21 (L858R), confer sensitivity to EGFR tyrosine kinase inhibitors
Autor:
Jaime L. Wolfe, Cynthia L. Sears, Shaoguang Wu, David L. Huso, Xinqun Wu, Drew M. Pardoll, Abby L. Geis, Hongni Fan, Franck Housseau
Publikováno v:
Cancer Discovery. 5:1098-1109
Many epithelial cancers are associated with chronic inflammation. However, the features of inflammation that are procarcinogenic are not fully understood. Regulatory T cells (Treg) typically restrain overt inflammatory responses and maintain intestin
Autor:
Antonella Bacchiocchi, Roger S. Lo, Richard F. Kefford, Georgina V. Long, Gulietta M. Pupo, Richard C. Koya, Jeffrey A. Sosman, Ramin Nazarian, Hubing Shi, Gatien Moriceau, Ruth Halaban, Antoni Ribas, Bartosz Chmielowski, Kimberly B. Dahlman, Xiangju Kong
Publikováno v:
Cancer Discovery. 2:414-424
BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced V600E/KBRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with V600E/KBRAF may be selected
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.